Antithrombotic drugs in secondary stroke prevention among a community dwelling older population

Landi F; Cesari M; Onder G; Zamboni V; Lattanzio F; Russo A; Barillaro C; Bernabei R; Landi, F; Cesari, M; Onder, G; Zamboni, V; Lattanzio, F; Russo, A; Barillaro, C; Bernabei, R; SILVERNET-HC Study Group
August 2003
Journal of Neurology, Neurosurgery & Psychiatry;Aug2003, Vol. 74 Issue 8, p1100
Academic Journal
journal article
Background: Patients who suffer a cerebrovascular event are at high risk of a recurrence. Secondary prevention is crucial in reducing the burden of cerebrovascular disease.Objective: To estimate the percentage of stroke survivors receiving antiplatelet or anticoagulant drugs and to identify factors associated with such treatment.Design: Cross sectional retrospective cohort study.Methods: Data were analysed from a large collaborative observational study, the Italian "silver network" home care project, which collected data (from 1997 to 2001) on patients admitted to home care programmes (n = 5372). Twenty two home health agencies participated in evaluating the implementation of the minimum dataset for home care (MDS-HC) instrument. For the present study, 648 individuals with a diagnosis of stroke were selected and the initial MDS-HC assessment reported.Results: 70% of stroke survivors did not receive any antiplatelet or anticoagulant drugs (95% confidence interval (CI), 66.5 to 73.5). Among all age categories, aspirin and ticlopidine were the two most commonly prescribed drugs. Living alone (odds ratio (OR), 0.49 (95% CI, 0.24 to 0.89)), dependency in activities of daily living (0.66 (0.40 to 0.99)), cognitive impairment (0.58 (0.38 to 0.86)), and low educational level (0.58 (0.34 to 0.98)) were associated with a reduced likelihood of receiving secondary stroke prevention treatment. Cardiac arrhythmias, coronary artery disease, heart failure, and peripheral vascular disease were associated with the use of antiplatelet or anticoagulant treatment.Conclusions: Negative attitudes among physicians with respect to secondary stroke prevention are prevalent and reinforce the need for increased awareness of existing data on the risks and benefits for elderly individuals. Social problems and functional impairment may be issues concerning physicians when deciding whether or not the risks of treatment exceed the benefit.


Related Articles

  • ticlopidine.  // Davis's Drug Guide for Nurses, 10th edition;2007, p1144 

    This article presents a nurse's guide to the antiplatelet agent ticlopidine. Ticlopidine is indicated for the prevention of stroke in patients who have had a completed thrombotic stroke or precursors to stroke and are unable to tolerate aspirin. It inhibits platelet aggregation by changing the...

  • Ticlopidine was not better than aspirin for preventing recurrent stroke in African-Americans with noncadioembolic ischemic stroke: COMMENTARY. Johnston, S. Claiborne // ACP Journal Club;Jan/Feb2004, Vol. 140 Issue 1, p9 

    This article focuses on a study regarding aspirin and ticlopidine for prevention of recurrent stroke in Afro-American patients, published in the 2003 issue of "Journal of the American Medical Association." In the author's opinion, in studies of stroke prevention, results for whites may not be...

  • Antiplatelet Treatment in Ischemic Stroke Treatment. Pinto, Antonio; Di Raimondo, Domenico; Tuttolomondo, Antonino; Sciacca, Riccardo Di; Arnao, Valentina; La Placa, Sergio; Milio, Glauco; Miceli, Salvatore; Licata, Giuseppe // Current Topics in Medicinal Chemistry;Oct2009, Vol. 9 Issue 14, p1298 

    Antiplatelets represent a diverse group of agents that share the ability to reduce platelet activity through a variety of mechanisms. Antithrombotic agents are effective in the secondary prevention of ischemic strokes. Most strokes are caused by a sudden blockage of an artery in the brain...

  • The safety and efficacy of clopidogrel versus ticlopidine in Japanese stroke patients: combined results of two Phase III, multicenter, randomized clinical trials. Uchiyama, Shinichiro; Fukuuchi, Yasuo; Yamaguchi, Takenori // Journal of Neurology;Jun2009, Vol. 256 Issue 6, p888 

    Two Phase III studies comparing the safety and efficacy of clopidogrel with ticlopidine as antiplatelet agents for the secondary prevention of vascular events in patients with prior stroke were performed in Japan. Both studies were randomized, double-blind, double-dummy comparative trials with...

  • Neuroprotection in acute ischaemic stroke. II: Clinical potential. Davis, M.; Barer, D. // Vascular Medicine;1999, Vol. 4 Issue 3, p149 

    In the 4 years since our first article, there has been considerable progress in our under-standing of the pathophysiology of acute ischaemic stroke, and the results of well-conducted trials have at last begun to change everyday clinical practice. The timing of the various pro-cesses of the...

  • Effects of Anticoagulation on Infarct Size and Clinical Outcome in Acute Cardioembolic Stroke. Wakita, Masayuki; Yasaka, Masahiro; Minematsu, Kazuo; Yamaguchi, Takenori // Angiology;Sep/Oct2002, Vol. 53 Issue 5, p551 

    Effects of anticoagulation on infarct size and outcome have not been fully elucidated in patients with acute cardioembolic stroke, although the anticoagulation therapy reduces both occurrence and recurrence of ischemic stroke greatly. The authors retrospectively investigated the relationship of...

  • A Long-term Study of Cerebral Vascular Disease. Groch, Sigmund N.; McDevitt, Ellen; Wright, Irving S. // Annals of Internal Medicine;Sep61, Vol. 55 Issue 3, p358 

    Reports on certain characteristics of a group of patients with strokes studied at a large municipal hospital. Types of cerebral vascular disease that are seen in a large municipal hospital with a non-selective admission policy and an active emergency service; Suitability of the patient...

  • Medication withdrawal may be associated with stroke events.  // Cardiology Today;Apr2009, Vol. 12 Issue 4, p15 

    The article discusses a study which found an association between the perioperative discontinuation of anticoagulant and antiplatelet medication in patients with stroke and additional stroke burden.

  • RE-LY, ACTIVE offer options for reducing stroke risk in patients with AF.  // Hem/Onc Today;2/25/2010, Vol. 11 Issue 4, p34 

    The article discusses various studies on the roles of anticoagulation therapy in preventing stroke when treating patients with atrial fibrillation.


Read the Article


Sign out of this library

Other Topics